A monthly injection of buprenorphine BUP-XR is more effective than a placebo for treating opioid addiction, according to the results of a new study. This formulation is the extended release version.
A daily dose version of buprenorphine was approved by the FDA (US Food and Drug Administration) in 2002. It has been an effective treatment for opioid use disorder. Daily doses mean patients must commit to taking it each day; they may start to experience cravings for opioids once they get close to the end of the 24-hour cycle when they can take more medication.
Medication Assisted Therapy and Treatment for Opioid Addiction
Buprenorphine and methadone are both used in MAT (Medication Assisted Therapy) to treat opioid addiction. These medications are used in combination with behavioral counseling as part of a “whole patient” approach. The medications are used to control cravings and clients work with a counselor to develop new ways of thinking and responding to life stresses.
Extended Release Buprenorphine Called Sublocade
The extended-release version of buprenorphine was approved by the FDA in November 2017, which is being marketed under the brand name Sublocade. Approval was based on positive results in a Phase III human subjects study. The study has been published in The Lancet to make it available to the wider scientific community.
Double-Blind Study Conducted
Researchers divided 200 participants in the randomized, double-blind study into three groups. All of them had a mean duration of opioid use of between 11 and 12 years. Two of the groups were given different monthly doses of BUP-XR and one was given a placebo.
Both groups who were given BUP-XR reported “substantial portions of participants” abstaining from opioids. They also experienced relief from opioid withdrawal symptoms and control from cravings for opioids without having to take medication on a daily basis.